Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 21 | 2025 | 623 | 5.370 |
Why?
|
| Early Detection of Cancer | 10 | 2022 | 398 | 2.080 |
Why?
|
| Occult Blood | 8 | 2022 | 31 | 1.910 |
Why?
|
| Colonoscopy | 9 | 2022 | 244 | 1.760 |
Why?
|
| Colonic Neoplasms | 6 | 2024 | 257 | 1.290 |
Why?
|
| Adenoma | 3 | 2022 | 143 | 1.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 4 | 2025 | 200 | 0.990 |
Why?
|
| Lymphocytes | 3 | 2023 | 355 | 0.920 |
Why?
|
| Mass Screening | 7 | 2022 | 805 | 0.830 |
Why?
|
| Colonic Polyps | 2 | 2021 | 82 | 0.750 |
Why?
|
| Adenomatous Polyps | 1 | 2021 | 14 | 0.700 |
Why?
|
| Polyps | 1 | 2021 | 40 | 0.680 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 1291 | 0.640 |
Why?
|
| Anemia | 2 | 2023 | 341 | 0.600 |
Why?
|
| Guaiac | 1 | 2017 | 1 | 0.540 |
Why?
|
| Xylenes | 4 | 2007 | 13 | 0.520 |
Why?
|
| Prognosis | 9 | 2023 | 4804 | 0.510 |
Why?
|
| Inflammation | 3 | 2024 | 1435 | 0.500 |
Why?
|
| Body Composition | 3 | 2024 | 539 | 0.490 |
Why?
|
| Anti-Infective Agents, Local | 5 | 2007 | 68 | 0.470 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 10 | 0.420 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2022 | 19 | 0.370 |
Why?
|
| Diabetes Complications | 1 | 2013 | 194 | 0.360 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 214 | 0.360 |
Why?
|
| Aspirin | 1 | 2013 | 209 | 0.360 |
Why?
|
| Neutrophils | 3 | 2023 | 355 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 293 | 0.350 |
Why?
|
| Aged | 14 | 2025 | 20519 | 0.340 |
Why?
|
| Trypsin | 1 | 2010 | 81 | 0.340 |
Why?
|
| Microbiological Techniques | 1 | 2010 | 31 | 0.330 |
Why?
|
| Humans | 37 | 2025 | 127514 | 0.330 |
Why?
|
| Catheters | 1 | 2010 | 82 | 0.320 |
Why?
|
| Robotic Surgical Procedures | 2 | 2025 | 224 | 0.320 |
Why?
|
| C-Reactive Protein | 3 | 2025 | 444 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 6 | 2011 | 2519 | 0.320 |
Why?
|
| Drug Utilization | 1 | 2011 | 163 | 0.320 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 249 | 0.290 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 475 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2024 | 2048 | 0.280 |
Why?
|
| Thymol | 1 | 2007 | 2 | 0.280 |
Why?
|
| Pneumonia | 1 | 2011 | 336 | 0.260 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 80 | 0.260 |
Why?
|
| Middle Aged | 12 | 2025 | 27894 | 0.260 |
Why?
|
| Equipment Contamination | 2 | 2005 | 40 | 0.260 |
Why?
|
| Retrospective Studies | 8 | 2024 | 17081 | 0.260 |
Why?
|
| Chlorhexidine | 5 | 2006 | 47 | 0.250 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 972 | 0.250 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 204 | 0.250 |
Why?
|
| Escherichia coli | 2 | 2010 | 962 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 735 | 0.250 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3076 | 0.240 |
Why?
|
| Male | 18 | 2025 | 62896 | 0.240 |
Why?
|
| Prosthesis-Related Infections | 3 | 2005 | 183 | 0.230 |
Why?
|
| Glycopeptides | 1 | 2005 | 24 | 0.230 |
Why?
|
| Female | 21 | 2025 | 68771 | 0.230 |
Why?
|
| Urinary Tract Infections | 2 | 2007 | 316 | 0.230 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 882 | 0.220 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 2240 | 0.220 |
Why?
|
| Vancomycin | 1 | 2005 | 221 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1357 | 0.200 |
Why?
|
| Scotland | 3 | 2021 | 23 | 0.190 |
Why?
|
| Staphylococcal Infections | 3 | 2005 | 565 | 0.190 |
Why?
|
| United Kingdom | 2 | 2013 | 235 | 0.190 |
Why?
|
| Prospective Studies | 5 | 2021 | 6250 | 0.180 |
Why?
|
| Logistic Models | 2 | 2018 | 1791 | 0.180 |
Why?
|
| Age Factors | 3 | 2024 | 2814 | 0.170 |
Why?
|
| Sex Factors | 2 | 2016 | 1315 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2021 | 1501 | 0.170 |
Why?
|
| Candida albicans | 4 | 2007 | 83 | 0.170 |
Why?
|
| Morbidity | 1 | 2021 | 252 | 0.160 |
Why?
|
| Time Factors | 4 | 2016 | 6171 | 0.160 |
Why?
|
| Rabbits | 6 | 2007 | 626 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2022 | 2080 | 0.150 |
Why?
|
| Rectal Neoplasms | 2 | 2024 | 76 | 0.150 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1998 | 4 | 0.140 |
Why?
|
| Emergencies | 2 | 2016 | 180 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 320 | 0.140 |
Why?
|
| Spain | 1 | 2017 | 60 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 165 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 627 | 0.130 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 85 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2016 | 73 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2022 | 1659 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1055 | 0.120 |
Why?
|
| Minocycline | 4 | 2002 | 42 | 0.120 |
Why?
|
| Pregnancy, Twin | 1 | 2017 | 190 | 0.120 |
Why?
|
| Psychosocial Deprivation | 1 | 2015 | 4 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1388 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 1371 | 0.110 |
Why?
|
| Rifampin | 4 | 2002 | 118 | 0.110 |
Why?
|
| Iron | 1 | 2018 | 300 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12582 | 0.110 |
Why?
|
| Colon | 1 | 2017 | 353 | 0.110 |
Why?
|
| Survival Rate | 2 | 2016 | 2111 | 0.110 |
Why?
|
| Feces | 3 | 2022 | 702 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2007 | 823 | 0.110 |
Why?
|
| Obesity | 1 | 2025 | 2338 | 0.100 |
Why?
|
| Catheters, Indwelling | 3 | 2007 | 150 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2013 | 51 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 536 | 0.090 |
Why?
|
| Length of Stay | 2 | 2024 | 1378 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 1198 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 735 | 0.090 |
Why?
|
| Sonication | 1 | 2010 | 7 | 0.080 |
Why?
|
| Hemoglobins | 2 | 2022 | 313 | 0.080 |
Why?
|
| Hospitals, Veterans | 2 | 2011 | 341 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1239 | 0.080 |
Why?
|
| Staphylococcus epidermidis | 2 | 2002 | 40 | 0.080 |
Why?
|
| Colectomy | 2 | 2024 | 92 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 6718 | 0.080 |
Why?
|
| Antibiotics, Antitubercular | 2 | 2002 | 36 | 0.080 |
Why?
|
| Algorithms | 1 | 2016 | 1638 | 0.080 |
Why?
|
| Adult | 5 | 2024 | 30609 | 0.070 |
Why?
|
| Candidiasis | 2 | 2007 | 128 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3597 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 54 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 2 | 2002 | 295 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2011 | 393 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2021 | 4988 | 0.070 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 973 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 2005 | 241 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5160 | 0.060 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2007 | 81 | 0.060 |
Why?
|
| Antisepsis | 1 | 2006 | 7 | 0.060 |
Why?
|
| Bacterial Infections | 2 | 2007 | 322 | 0.060 |
Why?
|
| Disinfectants | 1 | 2006 | 29 | 0.060 |
Why?
|
| Candida | 1 | 2006 | 79 | 0.060 |
Why?
|
| Teicoplanin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2007 | 263 | 0.060 |
Why?
|
| Bacteria | 1 | 2007 | 515 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 637 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 25 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 484 | 0.050 |
Why?
|
| Intra-Abdominal Fat | 1 | 2022 | 61 | 0.050 |
Why?
|
| Bacterial Adhesion | 3 | 1998 | 102 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2024 | 256 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 239 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 117 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2021 | 247 | 0.040 |
Why?
|
| Animals | 7 | 2007 | 33213 | 0.040 |
Why?
|
| Catheterization, Central Venous | 2 | 1998 | 140 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 1998 | 31 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 40 | 0.040 |
Why?
|
| Bone Nails | 1 | 1998 | 26 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1998 | 20 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2024 | 518 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 562 | 0.030 |
Why?
|
| Blood | 1 | 1998 | 99 | 0.030 |
Why?
|
| Tibial Fractures | 1 | 1998 | 64 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 132 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 581 | 0.030 |
Why?
|
| Conservative Treatment | 1 | 2017 | 38 | 0.030 |
Why?
|
| Klebsiella Infections | 1 | 1997 | 61 | 0.030 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 33 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 1997 | 83 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1998 | 172 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 98 | 0.030 |
Why?
|
| Equipment Design | 1 | 1998 | 576 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 131 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 1997 | 482 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 138 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 425 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 10636 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 900 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2017 | 425 | 0.030 |
Why?
|
| Neurotoxins | 1 | 1993 | 58 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 631 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2014 | 374 | 0.020 |
Why?
|
| Monocytes | 1 | 1993 | 330 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1993 | 256 | 0.020 |
Why?
|
| Pregnancy | 2 | 2017 | 7426 | 0.020 |
Why?
|
| Brain Injuries | 1 | 1993 | 693 | 0.020 |
Why?
|
| Silver Sulfadiazine | 2 | 1998 | 9 | 0.020 |
Why?
|
| Colony Count, Microbial | 2 | 1998 | 86 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 1148 | 0.020 |
Why?
|
| Drug Combinations | 2 | 1998 | 271 | 0.020 |
Why?
|
| Catheterization | 1 | 2006 | 235 | 0.010 |
Why?
|
| Bacillus | 1 | 2002 | 36 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 9705 | 0.010 |
Why?
|
| Drug Stability | 1 | 1998 | 58 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1998 | 4448 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1998 | 126 | 0.010 |
Why?
|
| Mannose | 1 | 1997 | 22 | 0.010 |
Why?
|
| Fimbriae, Bacterial | 1 | 1997 | 40 | 0.010 |
Why?
|
| Random Allocation | 1 | 1998 | 419 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 121 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 1997 | 104 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 1997 | 57 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1998 | 614 | 0.010 |
Why?
|
| Half-Life | 1 | 1996 | 151 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 1996 | 46 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 1 | 1996 | 72 | 0.010 |
Why?
|
| Spinal Cord Injuries | 1 | 1997 | 274 | 0.010 |
Why?
|
| Ganglia, Parasympathetic | 1 | 1993 | 1 | 0.010 |
Why?
|
| Cross Infection | 1 | 1997 | 334 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1993 | 50 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 1485 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1993 | 82 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1993 | 113 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1422 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1993 | 130 | 0.010 |
Why?
|
| Microglia | 1 | 1993 | 129 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 12810 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 2901 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1993 | 654 | 0.000 |
Why?
|
| Texas | 1 | 1998 | 3565 | 0.000 |
Why?
|
| Adolescent | 1 | 2007 | 20156 | 0.000 |
Why?
|